MAP
MLTX icon

Moody Aldrich Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Moody Aldrich Partners’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-54,416
Closed -$2.57M – 200
2025
Q2 		$2.57M Sell
54,416
-829
-2% -$33.8K 0.5% 83
2025
Q1 		$2.16M Buy
+55,245
New +$2.38M 0.45% 81
2023
Q4 		– Sell
-25,655
Closed -$1.46M – 216
2023
Q3 		$1.46M Buy
+25,655
New +$1.42M 0.28% 99

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Moody Aldrich Partners's MLTX Position: Q3 2025 in Review

Moody Aldrich Partners sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 54,416 shares — an estimated $2.57M sold.

Moody Aldrich Partners first reported a position in MLTX in Q3 2023 and held it in 3 quarters. The position peaked at $2.57M in Q2 2025. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • Moody Aldrich Partners reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Moody Aldrich Partners sold 54,416 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $2.57M.
  • Moody Aldrich Partners first reported a position in MoonLake Immunotherapeutics in Q3 2023 and held it in 3 quarters.
  • Moody Aldrich Partners's MoonLake Immunotherapeutics position peaked at $2.57M in Q2 2025.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Moody Aldrich Partners's 13F filing for Q3 2025, filed 21 Oct 2025.